PT-141

The PT-141 evidence base cited here is 7 sources — 3 clinical, 2 review, 1 regulatory. Its strongest evidence is human — 3 clinical studies, most recently 2022 ("Safety Profile of Bremelanotide Across All Clinical Development"). Regulatory status: FDA-approved (Vyleesi).

• PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin agonist — FDA-approved as Vyleesi (June 2019) for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.
• It works CENTRALLY through brain melanocortin receptors (MC4R/MC3R in the hypothalamus) to act on sexual desire itself — fundamentally different from PDE5 inhibitors (Viagra/Cialis), which act peripherally on blood flow and don't touch desire.
• It's the FDA-approved descendant of Melanotan-2: Palatin re-engineered MT-2 to concentrate activity at MC4R/MC3R and reduce the MC1R tanning effect. The famous origin was an accidental MT-2 overdose that caused an 8-hour erection.

PT-141 (generic bremelanotide, brand Vyleesi) is a melanocortin-receptor agonist and the first and only FDA-approved treatment for female sexual dysfunction that works through the central nervous system rather than a hormonal or vascular pathway. It targets sexual desire at its neurological origin in the hypothalamus.

It's one of the few research peptides with genuine FDA approval, so this monograph leans on real Phase 3 data — but two honest notes up front: the approved effect size is modest, and it's approved only for premenopausal women with HSDD (the widespread male use is off-label). Everything below is research context, not medical advice.

Bremelanotide is a synthetic cyclic heptapeptide analog of α-MSH (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, ~1,025 Da), cyclized via a lactam bridge that locks it into a constrained shape — giving it both high receptor affinity and resistance to enzymatic breakdown (elimination half-life ~2.7 hours, with effects outlasting plasma levels).

It descends directly from Melanotan-2. Palatin Technologies re-engineered MT-2 (swapping an amide for a hydroxyl group) to concentrate activity at the central MC4R/MC3R receptors that drive sexual response while dialing down the MC1R-mediated tanning of the parent compound. After the FDA placed a 2007 hold on an intranasal version over blood-pressure concerns, Palatin moved to subcutaneous dosing, which had a cleaner cardiovascular profile and carried it through the Phase 3 RECONNECT trials to approval.

FDA-approved dosing exists for the female HSDD indication; male/off-label figures are included for research context only.

• FDA (Vyleesi): 1.75 mg subcutaneously, ≥45 minutes before anticipated activity.
• Maximum one dose per 24 hours; maximum 8 doses per month. Not for daily use — keep to the minimum effective frequency.
• Off-label (men): typically the same 1.75 mg SC; some clinicians use 1–2 mg by response. First-timers may start lower (0.5–1 mg) to gauge nausea tolerance.
• Ondansetron ~30 min before can blunt nausea.

Timing: peak plasma at 30–60 min, maximal effect 2–4 hours; many find injecting 1–2 hours before activity optimal. The 24-hour and monthly caps exist to limit cumulative blood-pressure effect.

Subcutaneous injection. The approved Vyleesi product is a single-dose pre-filled auto-injector (1.75 mg / 0.3 mL); research-grade powder requires reconstitution.

• Sites: abdomen (preferred) or anterior thigh; alcohol-clean, pinch a fold, inject at 45–90°, hold, then gentle pressure (don't rub). Rotate sites.
• SC bioavailability is ~100% and far more predictable than the abandoned intranasal route (some compounding pharmacies still offer nasal spray off-label).

• 0–30 min: peptide enters circulation; nausea, if any, usually starts here.
• 30–60 min: peak plasma; initial onset for many; flushing/warmth may appear.
• 1–4 hours: maximal window for desire/arousal effects; blood-pressure elevation also peaks 2–4 hrs.
• 4–8 hours: effects taper (biological effect outlasts the ~2.7 hr plasma half-life via receptor residence).
• 8–12 hours: BP/heart rate back to baseline; systemic clearance essentially complete.

Onset varies widely — some report effects in 15–20 min, others up to 90 min. The label advises finding your own optimal timing by experience.

Anchored by real Phase 3 data — and worth reading honestly, because the effect is statistically significant but modest.

• RECONNECT (two identical Phase 3 RCTs, 1,267 premenopausal HSDD women): both met both co-primary endpoints — significant increases in desire (FSFI-D, P<0.001) and reduced distress (P<0.001) vs placebo.
• Effect size: ~25% of treated women achieved a ≥1.2 desire-score increase vs ~17% on placebo — real, but a modest absolute difference.
• Open-label extension: benefits maintained with continued on-demand use, no new safety signals.
• Male ED: ~33.5% positive response vs 8.5% placebo; salvage benefit in sildenafil non-responders. A combination-with-PDE5 program is ongoing.

The honest read: PT-141 is a validated, novel mechanism, but the approved benefit is incremental, not dramatic. FDA-approved Vyleesi is the only formulation with guaranteed manufacturing standards.

Usually a standalone agent. Research context, not protocol advice.

• PT-141 + PDE5 inhibitor (sildenafil) — studied for refractory ED with synergistic signal, BUT combined risk of hypertension and (in men) priapism; only under direct medical supervision.
• PT-141 + Melanotan-2 — do NOT combine; overlapping melanocortin activity amplifies effects and side effects unpredictably. Some alternate them on separate occasions (MT-2 for tan, PT-141 for sexual function).
• PT-141 + BPC-157 / GH secretagogues — unrelated mechanisms, no established interaction, but multi-peptide regimens complicate side-effect management.

• Vyleesi: pre-filled auto-injector, no reconstitution; store 20–25°C.
• Research-grade powder (typically 10 mg vials): reconstitute with bacteriostatic water down the vial wall, swirl gently, don't shake; clear/colorless only. Common ratio: 2 mL per 10 mg = 5 mg/mL (1.75 mg = 0.35 mL / 35 units on an insulin syringe).
• Unreconstituted: store desiccated below −18°C long-term (stable ~3 weeks at room temp). Reconstituted: 2–8°C, use within ~30 days; protect from light; avoid freeze-thaw.

Well-characterized from clinical trials. Nausea dominates, and there's a real (if transient) cardiovascular signal.

The BP elevation is why the FDA held the intranasal form in 2007; the CV warning remains on the Vyleesi label. No boxed warning, but BP should be controlled before use.

• FDA-approved as Vyleesi for ONE indication: acquired, generalized HSDD in premenopausal women. Prescription-only.
• Off-label prescribing (men, other indications) is legal at a physician's discretion but unsupported by FDA labeling.
• Available via compounding pharmacies (injectable or nasal) — not held to FDA manufacturing standards; quality varies.
• Widely sold as a 'research chemical' for lab use only — unregulated, purity unverified. Not approved outside the US in most countries.

Bremelanotide isn't named on the 2026 WADA Prohibited List, but as a synthetic peptide-hormone/melanocortin-agonist it plausibly falls under the broad S2 (peptide hormones, growth factors, mimetics) language, prohibited in- and out-of-competition. Its parent compound Melanotan-2 IS explicitly banned, a TUE for HSDD would be near-impossible to justify for an athlete, and research-grade product can carry undeclared substances — tested athletes should treat PT-141 as strictly off-limits.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.